2022 annual results and activity update
– TG4050: New Phase I data confirms the clinical and commercial potential of this innovative personalized immunotherapy. Preparation of a Phase II trial in head and neck cancer, the aim of which is to provide data for potential authorization.
– TG4001: Positive interim analysis allowing the continuation of the randomized Phase II clinical trial. Final results communicated in 2024. Transgene is preparing a registration study.
– Oncolytic viruses: New clinical data confirms the potential of Invir.IO® oncolytic viruses to be administered intravenously. Launch of TG6050, a new multi-armed oncolytic virus targeting a major indication in oncology.
– €26.8 million in available cash as of December 31, 2022, providing financial visibility until early 2024.
Conference call in English today at 6 p.m. (details at the end of the press release)